RVMD Q4 2023 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$742,000-95.2% YoY

Gross Profit

$742,000100.0% margin

Operating Income

-$180M-24256.5% margin

Net Income

-$162M-21770.5% margin

EPS (Diluted)

$-1.14

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$121M

Free Cash Flow

-$123M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$236M

Stockholders' Equity

$1.8B

Cash & Equivalents

$696M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$742,000	$15M	-95.2%
Gross Profit	$742,000	$15M	-95.2%
Operating Income	-$180M	-$62M	-191.7%
Net Income	-$162M	-$57M	-185.9%